Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Precisely mapped allosteric binding site will facilitate design of drugs with minimal side effects

Structural biologists at Cold Spring Harbor Laboratory (CSHL) have obtained a precise molecular map of the binding site for an allosteric inhibitor in a subtype of the NMDA (N-methyl-D-aspartate) receptor, which is commonly expressed in brain cells.

17 Jun 2011

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Celgene International Sàrl announced that clinical data from two studies evaluating the use of REVLIMID® (lenalidomide) with standard R-CHOP chemotherapy in patients with untreated diffuse large B cell (DLBCL) or grade 3 follicular lymphoma were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

17 Jun 2011

Public Health Grid technology could address specific surveillance needs for pandemic disease control

An evaluation of the Public Health Grid (PHGrid) technology during the 2009 H1N1 influenza pandemic could enhance the capabilities of epidemiologists and disease-control agencies when the next emergent disease appears, according to a study published in the International Journal of Grid and Utility Computing.

17 Jun 2011

Boosting immune response could increase inflammation

People often talk about "boosting" their immunity to prevent and fight colds. Nutritional supplements, cold remedies and fortified foods claim to stave off colds by augmenting the immune system.

16 Jun 2011

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. CXA-201 was studied for the treatment of complicated intra-abdominal infections (cIAI) in adults.

16 Jun 2011

Positive results from BiondVax Multimeric-001 Phase IIa trial against influenza

BiondVax Pharmaceuticals Ltd. today announced positive results from its first Phase II clinical trial of the Multimeric-001 Universal Influenza Vaccine.

16 Jun 2011

Geisinger uses mandatory approach to improve healthcare worker influenza vaccination rates

Geisinger Health System vaccinated more than 92% of all employees against influenza this season, with a modification of a mandatory program. On average, fewer than half of all healthcare workers receive flu vaccinations.

16 Jun 2011

Serious RSV infections may occur in previously healthy infants and children

For most parents, respiratory syncytial virus (RSV) isn't a familiar term. But it's a common cause of serious respiratory infections with a major impact on the health of infants and young children worldwide, according to a special CDC Review Article in the June issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

16 Jun 2011

Inviragen commences INV21 Phase 1 trial against Hand, Foot and Mouth Disease

Inviragen announced today the initiation of the first clinical trial of the Company's proprietary Hand, Foot and Mouth Disease (HFMD) investigational vaccine, INV21, a highly purified virus particle preparation designed to protect against HFMD caused by enterovirus 71.

16 Jun 2011

High proportion of men with prostate cancer die from the disease

Up to half the number of men with prostate cancer who die do so as a direct result of the disease, rather than from other causes according to a new study presented at the National Cancer Intelligence Network conference in London.

15 Jun 2011

GlycoVaxyn's Second Annual Science Day to highlight challenges of vaccine industry

GlycoVaxyn AG, a leader in the development of conjugate vaccines, today announced that it will host its Second Annual Science Day to discuss challenges and opportunities in vaccine development on June 16-17, 2011, in Cannes, France.

15 Jun 2011

Novartis Bexsero pivotal study data on meningococcal serogroup B presented at ESPID

New data from a pivotal study in more than 1,800 infants show that Novartis candidate vaccine Bexsero induces a robust immune response to meningococcal serogroup B when given alone or when co-administered with other routine vaccines.

15 Jun 2011

Universal influenza vaccination may reduce health care costs in the U.S.

Implementing a recommendation that all Americans be vaccinated against influenza may dramatically reduce health care costs and the number of people infected with seasonal influenza in the United States.

14 Jun 2011

Development through foreign aid requires global cooperation

The GAVI Alliance pledging conference is "being seen as a litmus test of how well aid can survive in the age of austerity," columnist Madeleine Bunting writes in a Guardian commentary, addressing how foreign aid is viewed as "soft power … to establish influence and spread values - which is often more useful than diplomacy or defence in a post-cold war world."

14 Jun 2011

Scientists identify six influenza A viruses similar to 2009 pandemic strain

Scientists using new mathematical and computational techniques have identified six influenza A viruses that have particularly close genetic relationships to the H1N1 "swine" flu virus that swept through the United States beginning in the spring of 2009. That virus eventually killed almost 18,000 people worldwide.

14 Jun 2011

Dengue vaccine could be available in four years

A vaccine against the mosquito-borne infection dengue, the first to reach the final stage of clinical testing, "has seen 'very promising' results in Thailand, a specialist involved in the tests said on Friday," Reuters reports.

14 Jun 2011

Cinryze data on hereditary angioedema presented at EAACI 2011

ViroPharma Incorporated today announced that data relating to Cinryze from nine accepted abstracts were presented as poster presentations at the 30th Congress of the European Academy of Allergy and Clinical Immunology (EAACI), June 11 through 15, in Istanbul, Turkey.

14 Jun 2011

Cypress receives FDA approval for ZUTRIPRO, REZIRA NDA to treat cough and common cold

Cypress Pharmaceutical announced today that the Food and Drug Administration (FDA) approved a new drug application (NDA) for ZUTRIPRO Oral Solution (CIII) and REZIRA Oral Solution.

14 Jun 2011

Billions committed for children’s vaccines

British Prime Minister David Cameron has pledged £814m to help vaccinate children around the world against preventable diseases like pneumonia. He made the announcement at a summit in London where countries are being asked to give an extra £2.3bn ($3.7bn) by 2015 for child vaccines. He said, “Three children die every minute from pneumonia alone. Waiting is not the right thing to do and I don't think that 0.7 per cent of our gross national income is too high a price to pay for saving lives.”

13 Jun 2011

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two ongoing Phase I studies with MLN9708, the first oral proteasome inhibitor being studied in patients with relapsed and/or refractory multiple myeloma.

13 Jun 2011

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Precisely mapped allosteric binding site will facilitate design of drugs with minimal side effects

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Public Health Grid technology could address specific surveillance needs for pandemic disease control

Boosting immune response could increase inflammation

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Positive results from BiondVax Multimeric-001 Phase IIa trial against influenza

Geisinger uses mandatory approach to improve healthcare worker influenza vaccination rates

Serious RSV infections may occur in previously healthy infants and children

Inviragen commences INV21 Phase 1 trial against Hand, Foot and Mouth Disease

High proportion of men with prostate cancer die from the disease

GlycoVaxyn's Second Annual Science Day to highlight challenges of vaccine industry

Novartis Bexsero pivotal study data on meningococcal serogroup B presented at ESPID

Universal influenza vaccination may reduce health care costs in the U.S.

Development through foreign aid requires global cooperation

Scientists identify six influenza A viruses similar to 2009 pandemic strain

Dengue vaccine could be available in four years

Cinryze data on hereditary angioedema presented at EAACI 2011

Cypress receives FDA approval for ZUTRIPRO, REZIRA NDA to treat cough and common cold

Billions committed for children’s vaccines

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Newsletters you may be interested in